Rates of hospitalizations with long-term rifaximin administration remained low : the HE-related hospitalization rate , normalized for exposure ( 0.21 ; all-rifaximin population ) , was similar to that of the rifaximin group in the original RCT ( 0.30 ) , and lower than that for the placebo group ( 0.72 ) .